Protara Therapeutics, based in New York, develops treatments for rare diseases and is conducting Phase II trials for its lead candidate, TARA-002, in non-muscle invasive bladder cancer and lymphatic malformations. The company also works on IV Choline Chloride for patients needing parenteral nutrition.
TARA filed a patent for "combination of non-viable cells of streptococcus pyogenes and immune checkpoint inhibitor for the treatment of non-muscle invasive bladder cancer" on Mon, February 27, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
